BridgeBio Pharma Announces Pricing Of 5,000,000-Share Secondary Offering By Selling Stockholder KKR Genetic Disorder; Company Receives No Proceeds

Loading news article.

BridgeBio Pharma Announces Pricing Of 5,000,000-Share Secondary Offering By Selling Stockholder KKR Genetic Disorder; Company Receives No Proceeds | WAPE

BridgeBio Pharma Announces Pricing Of 5,000,000-Share Secondary Offering By Selling Stockholder KKR Genetic Disorder; Company Receives No Proceeds

Article summary

Related companies

Comments —